STOCK TITAN

[Form 4] KORU Medical Systems, Inc. Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

KORU Medical Systems director Robert Cascella reported an open-market purchase of 3,916 shares of KORU Medical Systems, Inc. (KRMD) on 10/02/2025 at a reported price of $3.83 per share. After the transaction he beneficially owned 88,531 shares. The Form 4 was signed by an attorney-in-fact and includes a standard remark that a power of attorney has been previously filed.

Il direttore di KORU Medical Systems, Robert Cascella, ha riferito un acquisto sul mercato aperto di 3,916 azioni di KORU Medical Systems, Inc. (KRMD) il 10/02/2025 ad un prezzo riportato di $3.83 per azione. Dopo la operazione deteneva 88,531 azioni in modo beneficiario. Il Form 4 è stato firmato da un procuratore e include una nota standard secondo cui è stato precedentemente presentato un mandato.

El director de KORU Medical Systems, Robert Cascella, informó una compra en el mercado abierto de 3,916 acciones de KORU Medical Systems, Inc. (KRMD) el 10/02/2025 a un precio reportado de $3.83 por acción. Después de la operación poseía beneficiosamente 88,531 acciones. El Formulario 4 fue firmado por un apoderado e incluye una observación estándar de que se ha presentado previamente un poder.

KORU Medical Systems의 이사 Robert CascellaKRMD의 주식 3,916주를 10/02/2025에 공개시장에서 매수했다고 보고했다. 매매가의 보고 가격은 $3.83 per 주였다. 거래 후 그는 실질적으로 88,531주를 보유하게 되었다. Form 4는 대리인에 의해 서명되었고, 대리권은 이미 제출되었다는 표준 주석이 포함되어 있다.

Le directeur de KORU Medical Systems, Robert Cascella, a signalé l’achat sur le marché libre de 3 916 actions de KORU Medical Systems, Inc. (KRMD) le 10/02/2025 à un prix rapporté de 3,83 $ par action. Après la transaction, il détenait bénévolement 88 531 actions. Le Formulaire 4 a été signé par un mandataire et comprend une remarque standard indiquant qu'une procuration a été préalablement déposée.

Der Direktor von KORU Medical Systems, Robert Cascella, meldete einen Kauf am offenen Markt von 3.916 Aktien der KORU Medical Systems, Inc. (KRMD) am 10/02/2025 zu einem berichteten Preis von $3.83 pro Aktie. Nach der Transaktion besaß er beneficial 88.531 Aktien. Das Formular 4 wurde von einem Bevollmächtigten unterzeichnet und enthält eine Standardbemerkung, dass eine Vollmacht bereits eingereicht wurde.

مدير شركة KORU Medical Systems، Robert Cascella، أبلغ عن شراء في السوق المفتوح لـ 3,916 أسهم من KORU Medical Systems, Inc. (KRMD) في 10/02/2025 بسعر مُبلغ عنه قدره $3.83 للسهم. بعد الصفقة أصبح يملك فعلياً 88,531 أسهم. تم توقيع النموذج 4 من قِبل وكيـل قانوني ويتضمن ملاحظة معيارية تفيد بأنه قد تم تقديم توكيل سابقاً.

KORU Medical Systems 董事 Robert Cascella 报告在公开市场购买了 3,916 股 KORU Medical Systems, Inc. (KRMD),日期为 10/02/2025,每股报价为 $3.83。交易后他实际持有 88,531 股。该 Form 4 由一名代理人签署,并包含一项标准说明,指示已提前提交委托书。

Positive
  • Director purchase: Acquisition of 3,916 shares at $3.83
  • Increased insider ownership: Beneficial ownership rose to 88,531 shares
Negative
  • None.

Insights

Director purchased 3,916 KRMD shares at $3.83.

This Form 4 discloses a single non-derivative acquisition on 10/02/2025 that increased the reporting person's beneficial holdings to 88,531 shares. The filing is routine and executed via an attorney-in-fact, as stated.

The disclosure contains no derivative transactions, amendments, or other material conditions; it reports only the one equity purchase and the existing power-of-attorney remark.

Il direttore di KORU Medical Systems, Robert Cascella, ha riferito un acquisto sul mercato aperto di 3,916 azioni di KORU Medical Systems, Inc. (KRMD) il 10/02/2025 ad un prezzo riportato di $3.83 per azione. Dopo la operazione deteneva 88,531 azioni in modo beneficiario. Il Form 4 è stato firmato da un procuratore e include una nota standard secondo cui è stato precedentemente presentato un mandato.

El director de KORU Medical Systems, Robert Cascella, informó una compra en el mercado abierto de 3,916 acciones de KORU Medical Systems, Inc. (KRMD) el 10/02/2025 a un precio reportado de $3.83 por acción. Después de la operación poseía beneficiosamente 88,531 acciones. El Formulario 4 fue firmado por un apoderado e incluye una observación estándar de que se ha presentado previamente un poder.

KORU Medical Systems의 이사 Robert CascellaKRMD의 주식 3,916주를 10/02/2025에 공개시장에서 매수했다고 보고했다. 매매가의 보고 가격은 $3.83 per 주였다. 거래 후 그는 실질적으로 88,531주를 보유하게 되었다. Form 4는 대리인에 의해 서명되었고, 대리권은 이미 제출되었다는 표준 주석이 포함되어 있다.

Le directeur de KORU Medical Systems, Robert Cascella, a signalé l’achat sur le marché libre de 3 916 actions de KORU Medical Systems, Inc. (KRMD) le 10/02/2025 à un prix rapporté de 3,83 $ par action. Après la transaction, il détenait bénévolement 88 531 actions. Le Formulaire 4 a été signé par un mandataire et comprend une remarque standard indiquant qu'une procuration a été préalablement déposée.

Der Direktor von KORU Medical Systems, Robert Cascella, meldete einen Kauf am offenen Markt von 3.916 Aktien der KORU Medical Systems, Inc. (KRMD) am 10/02/2025 zu einem berichteten Preis von $3.83 pro Aktie. Nach der Transaktion besaß er beneficial 88.531 Aktien. Das Formular 4 wurde von einem Bevollmächtigten unterzeichnet und enthält eine Standardbemerkung, dass eine Vollmacht bereits eingereicht wurde.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
CASCELLA ROBERT

(Last) (First) (Middle)
C/O KORU MEDICAL SYSTEMS, INC.
100 CORPORATE DRIVE

(Street)
MAHWAH NJ 07430

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
KORU Medical Systems, Inc. [ KRMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
10/02/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 10/02/2025 A 3,916 A $3.83 88,531 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
Remarks:
The filing of this statement shall not be construed as an admission (a) that the person filing this statement is, for the purposes of Section 16 of the Securities Exchange Act of 1934, as amended, the beneficial owner of any equity securities covered by this statement, or (b) that this statement is legally required to be filed by such person. Power of Attorney has been previously filed.
/s/ Thomas Adams- Attorney-in-Fact 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the Form 4 for KORU Medical Systems (KRMD) disclose?

It disclosed a director purchase of 3,916 shares on 10/02/2025 at $3.83, bringing beneficial ownership to 88,531 shares.

Who filed the Form 4 for KRMD?

The reporting person is Robert Cascella, identified as a director; the form was signed by Thomas Adams as attorney-in-fact.

Were any derivative securities reported on this Form 4 for KRMD?

No. Table II (derivative securities) contains no reported transactions or holdings.

Does the filing indicate any amendments or special conditions?

No amendment date is provided and the remarks note only that a Power of Attorney has been previously filed.

On what date did the reported transaction occur?

The transaction date reported is 10/02/2025.
Koru Med Sys

NASDAQ:KRMD

KRMD Rankings

KRMD Latest News

KRMD Latest SEC Filings

KRMD Stock Data

181.70M
42.38M
8.29%
55.73%
2.53%
Medical Instruments & Supplies
Surgical & Medical Instruments & Apparatus
Link
United States
MAHWAH